PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion

Immunity

Volumn 44, Issue 5, 2016, Pages 1190-1203

  Tinoco, Roberto ^a,b   Carrette, Florent ^a   Barraza, Monique L ^a   Otero, Dennis C ^a   Magaña, Jonathan ^a   Bosenberg, Marcus W ^c   Swain, Susan L ^d   Bradley, Linda M ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Immunopathology; Inhibitory receptors; Lymphocytic choriomeningitis virus clone 13; Melanoma; P selectin glycoprotein ligand 1; Programmed death 1; T cell exhaustion

Indexed keywords

INTERLEUKIN 2; P SELECTIN GLYCOPROTEIN LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; P-SELECTIN LIGAND PROTEIN; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IMMUNOPATHOLOGY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE EXHAUSTION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HUMAN; IMMUNE EVASION; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MELANOMA; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE EVASION; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION;

EID: 84966762486     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.04.015     Document Type: Article

References (48)

1. Aubert R.D., Kamphorst A.O., Sarkar S., Vezys V., Ha S.J., Barber D.L., Ye L., Sharpe A.H., Freeman G.J., Ahmed R. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc. Natl. Acad. Sci. USA 2011, 108:21182-21187.
2. Baldwin T.A., Hogquist K.A. Transcriptional analysis of clonal deletion in vivo. J. Immunol. 2007, 179:837-844.
3. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
4. Bennett F., Luxenberg D., Ling V., Wang I.M., Marquette K., Lowe D., Khan N., Veldman G., Jacobs K.A., Valge-Archer V.E., et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J. Immunol. 2003, 170:711-718.
5. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., Betts M.R., Freeman G.J., Vignali D.A., Wherry E.J. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10:29-37.
6. Blattman J.N., Grayson J.M., Wherry E.J., Kaech S.M., Smith K.A., Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 2003, 9:540-547.
7. Borges E., Eytner R., Moll T., Steegmaier M., Campbell M.A., Ley K., Mossmann H., Vestweber D. The P-selectin glycoprotein ligand-1 is important for recruitment of neutrophils into inflamed mouse peritoneum. Blood 1997, 90:1934-1942.
8. Brooks D.G., Trifilo M.J., Edelmann K.H., Teyton L., McGavern D.B., Oldstone M.B. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 2006, 12:1301-1309.
9. Brooks D.G., Ha S.J., Elsaesser H., Sharpe A.H., Freeman G.J., Oldstone M.B. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc. Natl. Acad. Sci. USA 2008, 105:20428-20433.
10. Carlow D.A., Gossens K., Naus S., Veerman K.M., Seo W., Ziltener H.J. PSGL-1 function in immunity and steady state homeostasis. Immunol. Rev. 2009, 230:75-96.
11. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat. Rev. Cancer 2003, 3:559-570.
12. Dankort D., Curley D.P., Cartlidge R.A., Nelson B., Karnezis A.N., Damsky W.E., You M.J., DePinho R.A., McMahon M., Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 2009, 41:544-552.
13. Engelhardt B., Kempe B., Merfeld-Clauss S., Laschinger M., Furie B., Wild M.K., Vestweber D. P-selectin glycoprotein ligand 1 is not required for the development of experimental autoimmune encephalomyelitis in SJL and C57BL/6 mice. J. Immunol. 2005, 175:1267-1275.
14. Frebel H., Nindl V., Schuepbach R.A., Braunschweiler T., Richter K., Vogel J., Wagner C.A., Loffing-Cueni D., Kurrer M., Ludewig B., Oxenius A. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J. Exp. Med. 2012, 209:2485-2499.
15. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013, 14:1014-1022.
16. Haddad W., Cooper C.J., Zhang Z., Brown J.B., Zhu Y., Issekutz A., Fuss I., Lee H.O., Kansas G.S., Barrett T.A. P-selectin and P-selectin glycoprotein ligand 1 are major determinants for Th1 cell recruitment to nonlymphoid effector sites in the intestinal lamina propria. J. Exp. Med. 2003, 198:369-377.
17. Kao C., Oestreich K.J., Paley M.A., Crawford A., Angelosanto J.M., Ali M.A., Intlekofer A.M., Boss J.M., Reiner S.L., Weinmann A.S., Wherry E.J. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat. Immunol. 2011, 12:663-671.
18. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
19. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 2015, 373:23-34.
20. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007, 7:678-689.
21. Lin W.M., Baker A.C., Beroukhim R., Winckler W., Feng W., Marmion J.M., Laine E., Greulich H., Tseng H., Gates C., et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008, 68:664-673.
22. + T cells. Immunity 2015, 42:265-278.
23. Matloubian M., Concepcion R.J., Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 1994, 68:8056-8063.
24. Matsumoto M., Miyasaka M., Hirata T. P-selectin glycoprotein ligand-1 negatively regulates T-cell immune responses. J. Immunol. 2009, 183:7204-7211.
25. Moskophidis D., Lechner F., Pircher H., Zinkernagel R.M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993, 362:758-761.
26. Nakano H., Gunn M.D. Gene duplications at the chemokine locus on mouse chromosome 4: multiple strain-specific haplotypes and the deletion of secondary lymphoid-organ chemokine and EBI-1 ligand chemokine genes in the plt mutation. J. Immunol. 2001, 166:361-369.
27. Paley M.A., Kroy D.C., Odorizzi P.M., Johnnidis J.B., Dolfi D.V., Barnett B.E., Bikoff E.K., Robertson E.J., Lauer G.M., Reiner S.L., Wherry E.J. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012, 338:1220-1225.
28. Pellegrini M., Calzascia T., Toe J.G., Preston S.P., Lin A.E., Elford A.R., Shahinian A., Lang P.A., Lang K.S., Morre M., et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011, 144:601-613.
29. Petrovas C., Casazza J.P., Brenchley J.M., Price D.A., Gostick E., Adams W.C., Precopio M.L., Schacker T., Roederer M., Douek D.C., Koup R.A. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 2006, 203:2281-2292.
30. Sabbagh L., Pulle G., Liu Y., Tsitsikov E.N., Watts T.H. ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. J. Immunol. 2008, 180:8093-8101.
31. Sanjabi S., Mosaheb M.M., Flavell R.A. Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity 2009, 31:131-144.
32. Sheppard K.A., Fitz L.J., Lee J.M., Benander C., George J.A., Wooters J., Qiu Y., Jussif J.M., Carter L.L., Wood C.R., Chaudhary D. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004, 574:37-41.
33. Shin H., Blackburn S.D., Blattman J.N., Wherry E.J. Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J. Exp. Med. 2007, 204:941-949.
34. Sullivan J.A., Kim E.H., Plisch E.H., Suresh M. FOXO3 regulates the CD8 T cell response to a chronic viral infection. J. Virol. 2012, 86:9025-9034.
35. Tinoco R., Alcalde V., Yang Y., Sauer K., Zuniga E.I. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity 2009, 31:145-157.
36. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
37. Urzainqui A., Serrador J.M., Viedma F., Yáñez-Mó M., Rodríguez A., Corbí A.L., Alonso-Lebrero J.L., Luque A., Deckert M., Vázquez J., Sánchez-Madrid F. ITAM-based interaction of ERM proteins with Syk mediates signaling by the leukocyte adhesion receptor PSGL-1. Immunity 2002, 17:401-412.
38. Urzainqui A., Martínez del Hoyo G., Lamana A., de la Fuente H., Barreiro O., Olazabal I.M., Martin P., Wild M.K., Vestweber D., González-Amaro R., Sánchez-Madrid F. Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. J. Immunol. 2007, 179:7457-7465.
39. Veerman K.M., Williams M.J., Uchimura K., Singer M.S., Merzaban J.S., Naus S., Carlow D.A., Owen P., Rivera-Nieves J., Rosen S.D., Ziltener H.J. Interaction of the selectin ligand PSGL-1 with chemokines CCL21 and CCL19 facilitates efficient homing of T cells to secondary lymphoid organs. Nat. Immunol. 2007, 8:532-539.
40. Veerman K.M., Carlow D.A., Shanina I., Priatel J.J., Horwitz M.S., Ziltener H.J. PSGL-1 regulates the migration and proliferation of CD8(+) T cells under homeostatic conditions. J. Immunol. 2012, 188:1638-1646.
41. Virgin H.W., Wherry E.J., Ahmed R. Redefining chronic viral infection. Cell 2009, 138:30-50.
42. West E.E., Jin H.T., Rasheed A.U., Penaloza-Macmaster P., Ha S.J., Tan W.G., Youngblood B., Freeman G.J., Smith K.A., Ahmed R. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 2013, 123:2604-2615.
43. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
44. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 2003, 77:4911-4927.
45. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
46. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 1998, 188:2205-2213.
47. Zarbock A., Müller H., Kuwano Y., Ley K. PSGL-1-dependent myeloid leukocyte activation. J. Leukoc. Biol. 2009, 86:1119-1124.
48. Zinselmeyer B.H., Heydari S., Sacristán C., Nayak D., Cammer M., Herz J., Cheng X., Davis S.J., Dustin M.L., McGavern D.B. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J. Exp. Med. 2013, 210:757-774.